- Conditions
- Idiopathic Angioedema
- Interventions
- Omalizumab, Placebos
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 2,427
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Adults
- Interventions
- QRH-882260
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 25 Years to 100 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Knee Osteoarthritis, Acute Pain, Anesthesia, Local, Regional Anesthesia
- Interventions
- ropivacaine 0.25% with epinephrine and 6mg dexamethasone, Saline
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- Efprezimod alfa, Placebo
- Drug
- Lead sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 10
- States / cities
- Jacksonville, Florida • Annapolis, Maryland • Baltimore, Maryland + 7 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- PIV5-vectored RSV Vaccine (BLB-201) Low Dose, PIV5-vectored RSV Vaccine (BLB-201) High Dose, Placebo
- Biological · Drug
- Lead sponsor
- Blue Lake Biotechnology Inc.
- Industry
- Eligibility
- 6 Months to 5 Years
- Enrollment
- 137 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 18
- States / cities
- La Mesa, California • Modesto, California • San Diego, California + 14 more
- Conditions
- Lyme Disease
- Interventions
- VLA15, Saline
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 12,546 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 82
- States / cities
- Essex, Connecticut • Ledyard Center, Connecticut • New London, Connecticut + 67 more
- Conditions
- Uterine Atony With Hemorrhage
- Interventions
- Methylergonovine, Normal Saline (placebo)
- Drug
- Lead sponsor
- Cynthia Wong
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Covid19
- Interventions
- LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, MP0420, PF-07304814
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2,753 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 98
- States / cities
- Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more
- Conditions
- Heart Failure, Congestive, Cardiomyopathy
- Interventions
- recombinant B-type, natriuretic peptide, placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Osteoarthritis, Knee
- Interventions
- Intravenous tranexamic acid, Topical tranexamic acid, Intravenous saline, Topical saline
- Drug
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Coronary Artery Disease
- Interventions
- Methylnaltrexone, Placebo, Morphine, Ticagrelor
- Drug · Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Very Long-chain Acyl-CoA Dehydrogenase Deficiency, Trifunctional Protein Deficiency, Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Medium-chain Acyl-CoA Dehydrogenase Deficiency, Normal Volunteers, Carnitine Palmitoyltransferase II Deficiency, Myopathic
- Interventions
- Intralipid/Heparin, Glycerol/Saline, Hyperinsulinemic euglycemic clamp
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Advanced Solid Tumors
- Interventions
- palifosfamide-tris, Normal Saline
- Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 3
- States / cities
- Dallas, Texas • Houston, Texas • San Antonio, Texas
- Conditions
- Colorectal Cancer
- Interventions
- panitumumab
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Migraine, Headache, Episodic Migraine
- Interventions
- Lidocaine 4% Topical Application Cream [LMX 4], Lidocaine Hydrochloride 2 mg/mL Injectable Solution, Normal Saline
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 7 Years to 21 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- PTSD
- Interventions
- Oxytocin, Placebo
- Drug · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- San Francisco, California • Charleston, South Carolina
- Conditions
- Metabolic Syndrome, Insulin Sensitivity, Cardiovascular Diseases
- Interventions
- Phosphorus-supplemented study diet, Control Diet
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Lung Transplant, Complications Surgical
- Interventions
- Tranexamic Acid, Saline (placebo)
- Drug · Other
- Lead sponsor
- Corewell Health West
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- Asthma
- Interventions
- n-acetylcystine, 0.9% saline
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Von Willebrand Disease
- Interventions
- Recombinant von Willebrand factor (rVWF), Placebo, Recombinant factor VIIII (rFVIII)
- Biological · Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 10
- States / cities
- Sacramento, California • Miami, Florida • Peoria, Illinois + 7 more
- Conditions
- Surgery, Sedation
- Interventions
- Triazolam, Midazolam, Microcrystalline Cellulose, Sodium chloride 0.9%
- Drug
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- SARS-CoV-2, Influenza
- Interventions
- mRNA-1083, Placebo, Influenza Vaccine, COVID-19 Vaccine
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 8,061 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 146
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Cullman, Alabama + 122 more
- Conditions
- Recovery Time, Bruising
- Interventions
- Fibrinogen, Septorhinoplasty, Taping after septorhinoplasty., Cast applied to the nose after nasal surgery, Saline
- Drug · Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy, Heart Failure, Cardiomyopathies
- Interventions
- MYDICAR Phase 1, MYDICAR Phase 2, Placebo Phase 2 only
- Genetic
- Lead sponsor
- Celladon Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2015
- U.S. locations
- 4
- States / cities
- La Jolla, California • San Diego, California • Kansas City, Missouri + 1 more